Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00014937 · ClinicalTrials.gov registry record · NA
Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen
A NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- NA
- Development phase
- 240
- Enrollment target
NCT00014937 is a NA study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 240 participants.
The verdict
NCT00014937, a NA study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- NA
- Development phase
- 240 participants
- Enrollment target
Study Summary
ACTG 388 was a clinical trial that compared three- and four-drug anti-HIV drug regimens and demonstrated the effectiveness of a three-drug regimen. This study will compare the ability of two different three-drug anti-HIV drug regimens to reduce levels of HIV in the blood. The study will also evaluate whether patients discontinue the regimens because of drug side effects.
Interventions
- DRUG lamivudine
- DRUG efavirenz
- DRUG lopinavir/ritonavir
- DRUG stavudine
- DRUG lamivudine/zidovudine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00014937
The ClinicalTrials.gov registry entry for NCT00014937 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which lamivudine is the first listed.
NCT00014937 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00014937 about?
NCT00014937 is a clinical study titled "Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen". ACTG 388 was a clinical trial that compared three- and four-drug anti-HIV drug regimens and demonstrated the effectiveness of a three-drug regimen. This study will compare the ability of two different three-drug anti-HIV drug regimens to reduce levels of HIV in the blood. The study will also evaluat...
What is the current status of trial NCT00014937?
This trial is currently completed. It is a NA study. The enrollment target is 240 participants.
What interventions are being tested in trial NCT00014937?
The interventions under investigation include: lamivudine (DRUG), efavirenz (DRUG), lopinavir/ritonavir (DRUG), stavudine (DRUG), lamivudine/zidovudine (DRUG).
Who is sponsoring clinical trial NCT00014937?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.